Trials / Active Not Recruiting
Active Not RecruitingNCT05361434
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma in Adults
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 311 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world clinical practice. The decision to prescribe cabozantinib and nivolumab in combination will be made prior to, and independently from, the decision to enrol the participant in study.
Conditions
Timeline
- Start date
- 2022-09-26
- Primary completion
- 2025-10-20
- Completion
- 2026-11-30
- First posted
- 2022-05-04
- Last updated
- 2026-04-01
Locations
66 sites across 8 countries: Belgium, France, Greece, Italy, Norway, Saudi Arabia, South Korea, United Kingdom
Source: ClinicalTrials.gov record NCT05361434. Inclusion in this directory is not an endorsement.